Discovery Labs and FDA to Meet On June 2, 2009 to Discuss SURFAXIN Complete Response Letter
11 mai 2009 16h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., May 11, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) has received written notification from the U.S. Food and Drug Administration (FDA) that an end-of-review...
Discovery Labs to Raise $11.3 Million in Registered Direct Offering
08 mai 2009 15h06 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., May 8, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it has entered into definitive agreements with select institutional investors to raise...
Discovery Labs' Surfaxin(r) Significantly Improves Lung Surfactant Distribution in Preclinical RDS Model
05 mai 2009 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., May 5, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announced that data from a preclinical study using Surfaxin(r) (lucinactant) in a well-established preterm...
Discovery Labs' KL4 Surfactant Shows Physiologic and Survival Benefit in a Preclinical Model for Severe Respiratory Condition -- Acute Lung Injury
04 mai 2009 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., May 4, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced that data from a preclinical study using KL4 surfactant demonstrated a favorable physiologic...
Discovery Labs Receives Notice of Allowance for Patent to Treat Infants At Risk of Developing Bronchopulmonary Dysplasia
01 mai 2009 07h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., May 1, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO)...
Discovery Labs Reports First Quarter 2009 Financial Results
28 avr. 2009 17h55 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., April 28, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced financial results for the first quarter ended March 31, 2009.
For the quarter ended...
Discovery Labs Presents Pharmacoeconomic Data Linking Decreased Hospital Costs to Reduction in Reintubation Following Surfaxin Use
27 avr. 2009 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., April 27, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it presented a pharmacoeconomic analysis of data from its SELECT and STAR Phase 3...
Discovery Labs Receives Complete Response From FDA for Surfaxin(r) for Prevention of RDS
20 avr. 2009 07h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., April 20, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that, on April 17, 2009, it received a Complete Response letter from the U.S. Food and...
Discovery Labs Provides Update Regarding Surfactant Aerosol Generation Technology
14 avr. 2009 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., April 14, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces that it continues to make significant progress in the development of its proprietary...
Discovery Labs to Highlight Respiratory Pipeline at the Future Leaders in the Biotech Industry Conference
30 mars 2009 09h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., March 30, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) will present to the investment community at the BioCentury Future Leaders in the Biotech Industry...